Employees are watching more of their hard-earned wages disappear into premiums and deductibles. Insurers need to answer for why coverage costs so much and delivers so little. nytimes.com/2026/10/22/busin…

Patients benefit when pharmaceutical companies compete to develop better, more affordable treatments. The COINS Act should not create new barriers to innovation and competition. More treatment options, greater patient choice, and lower healthcare costs should be the goal.

Competition drives innovation, expands patient choice, and helps lower healthcare costs. But proposed COINS Act regulations could restrict investments in promising new medicines, creating more government barriers to the development of lifesaving treatments.

America's pharmaceutical industry leads the world in innovation because it has access to global scientific breakthroughs. Restricting international biotech partnerships risks slowing drug development, limiting patient access to new treatments, and driving up costs. Patients deserve better.

The COINS Act could create new barriers to global biotech partnerships, threatening America's leadership in pharmaceutical innovation. Policymakers must balance national security with the need to keep lifesaving treatments moving from research labs to patients.statnews.com/2026/10/23/new-…

Family health insurance now costs more than $28,000 a year, while workers’ premium contributions jumped 9%. American families and small businesses are being squeezed dry. When will greedy insurers stop padding their bottom lines at everyone else’s expense? usnews.com/news/national-new…

Part D accelerated innovation but challenge now is IRA price negotiations & MFN are harming innovation. Innovation is leaving US to go to China. Incentives here need to be centered around more cures. - @jwhite_health

Bipartisanship is vital to reforming #Medicare. Patients must have choice and still be able to access the medications they need. - @jwhite_health

CAHC’s @jwhite_health is participating in @MAPRx’s #Medicare Part D 20th anniversary summit. He is discussing the evolution & impact of the program with @LizFowler_ @PollyWebHC, Preston Bell and Rai Downs.

A handful of insurance giants dominate #healthcare, controlling everything from coverage, doctors & medication access. In @townhallcom, @jwhite_health argues breaking up those monopolies & restoring competition is critical to lowering costs & protecting patients. townhall.com/columnists/joel…

Michigan is suing BCBS over alleged anticompetitive practices that drive up costs. Patients deserve competition, not monopolies. modernhealthcare.com/insuran…

Importing a foreign system that limits access to cancer drugs risks creating similar challenges in the U.S. Whatever the label, GLOBE expands price controls, potentially restricting access without addressing affordability. cahc.net/price-controls-come…

“For too long, insurers have avoided the spirit of the law, which is to provide Americans with accurate information on lower costs. That ends today." - @jwhite_health cahc.net/strengthening-healt… #affordability #healthcare

Cleveland Clinic generated hundreds of millions of dollars through 340B while not passing those discounts directly to patients. That’s not what the program was meant to do. Congress needs to make sure 340B benefits patients, not hospital balance sheets. wkyc.com/article/news/health…

Americans deserve lower drug costs. @CMSGov's GLOBE Model takes the wrong approach — expanding govt price controls while failing to address the underlying drivers of high drug costs & potentially limiting patient access to cancer treatments. cahc.net/price-controls-come…

Congress and the administration should build on #Medicare's progress by reforming Part D and stabilizing the broader #healthcare market. cahc.net/medicare-stability-…